sponsored
PatientsVille.com Logo

PatientsVille

Neupro Medical Research Studies

Up-to-date List of Neupro Medical Research Studies

What Research is Being Done?

A clinical study involves research using human volunteers (also called participants) that is intended to add to medical knowledge. There are two main types of clinical studies: clinical trials (also called interventional studies) and observational studies. Following list includes both interventional and observational studies.

Latest Neupro Medical Research Studies

Rank Status Study
1 Not yet recruiting Switching From Oral Dopamine Agonists to Rotigotine
Conditions: Restless Legs Syndrome;   Ekbom Syndrome;   Willis-Ekbom Disease
Intervention: Drug: Rotigotine
Outcome Measures: Proportion of patients completing the switch and their adverse events;   International Restless Legs Scale (IRLS);   RLS-6 Scales;   Preference of Medication Scale (POM);   The Patient Global Impression of Change scale;   The Clinician Global Impression of Change Scale
2 Recruiting Single-site, Open-label, Randomized, Cross-over Study in Healthy Chinese Subjects to Evaluate the Bioequivalence of Single-dose Rotigotine Transdermal Patch Comparing 2 Different Formulations
Condition: Healthy
Interventions: Drug: Rotigotine PR2.2.1;   Drug: Rotigotine PR2.1.1
Outcome Measures: Area under the plasma concentration-time curve from zero up to the last analytically quantifiable concentration (AUC(0-t));   Area under the plasma concentration-time curve from zero up to Infinity (AUC);   The maximum plasma concentration of unconjugated Rotigotine (Cmax);   Area under the plasma concentration-time curve from zero up to the last analytically quantifiable concentration normalized by apparent dose (mg) (AUC(0-t) norm (apparent dose));   Area under the plasma concentration-time curve from zero up to the last analytically quantifiable concentration normalized by body weight (kg) (AUC(0-t) norm (BW));   Area under the plasma concentration-time curve from zero up to infinity normalized by apparent dose (mg) (AUCnorm (apparent dose));   Area under the plasma concentration-time curve from zero up to infinity normalized by body weight (kg) (AUCnorm (BW));   Maximum plasma concentration of unconjugated Rotigotine normalized by apparent dose (Cmax, norm (apparent dose));   Maximum plasma concentration of unconjugated Rotigotine normalized by body weight (Cmax, norm (BW));   Time to reach a maximum plasma concentration of unconjugated Rotigotine after patch application (tmax);   Mean residence time (MRT);   Rate constant of elimination (λz);   Terminal half-life (t1/2);   Relative bioavailability calculated based on Cmax (fCmax);   Relative bioavailability calculated based on AUC (fAUC);   Apparent total body clearance (CL/f)
3 Recruiting Effect of Rotigotine Patch Treatment on Cardiovascular Markers in Idiopathic Restless Legs Syndrome
Condition: Restless Legs Syndrome (RLS)
Interventions: Drug: Rotigotine;   Drug: Placebo patchs
Outcome Measures: Percentages of non-dippers(defined as <10% drop in BP during sleep)at 35+/-3 days;   Digital pulse amplitude measured by reactive hyperhemia with finger plethysmographic methodology;   PLMS and PLMS-microarousal indexes;   Amplitude of PLMS-related HR responses
4 Recruiting Possible Use of Rotigotine in Subjects 70 Years and Older With Late Onset of Disease
Condition: Parkinson's Disease
Intervention: Drug: Rotigotine
Outcome Measures: Percentage of Responders to treatment (*) in motor (part III) and Activities of daily living (ADL) (part II) components of Unified Parkinson's Disease Rating Scale (UPDRS) at visit 4 and 6;   Percentage of Responders to treatment in sleep quality in relation to Parkinson's Disease Sleep Scale-2 (PDSS) at visit 4 and 6
5 Recruiting Rotigotine Versus Placebo to Evaluate the Efficacy on Depressive Symptoms in Idiopathic Parkinson's Disease Patients
Condition: Idiopathic Parkinson's Disease
Interventions: Drug: Rotigotine;   Drug: Placebo Patch
Outcome Measures: Change from the Baseline to the end of Maintenance Period in the score of the Hamilton Depression Scale (HAM-D);   Change from Baseline to the end of Maintenance Period in the score of Beck Depression Inventory (BDI-II);   Change from Baseline to the end of Maintenance Period in the score of Unified Parkinson's Disease Rating Scale (UPDRS) part II (Activities of Daily Living-ADL subscale);   Change from Baseline to the end of Maintenance Period in the score of Unified Parkinson's Disease Rating Scale (UPDRS) part III (motor subscale);   Change from Baseline to the end of Maintenance Period in the combined score of Unified Parkinson's Disease Rating Scale (UPDRS) part II (ADL) plus part III (motor subscale);   Change from Baseline to the end of Maintenance Period in the score of Apathy Scale (AS);   Change from Baseline to the end of Maintenance Period in the score of Snaith-Hamilton Pleasure Scale (SHAPS)
6 Not yet recruiting Study to Assess Dopamine Receptor Modulation With Rotigotine to Enhance Morphine Analgesia in the Dental Model
Condition: Post-op Pain
Intervention: Drug: Neupro® transdermal patch/placebo
Outcome Measures: Sum of pain intensity difference scores;   Analgesic tablets taken postoperatively
7 Recruiting MIRT and Rotigotine in the Early Stage of PD
Condition: Parkinson's Disease
Interventions: Other: Multidisciplinary intensive rehabilitation treatment;   Drug: Rotigotine
Outcome Measures: UPDRS total score;   UPDRS II;   UPDRS III;   6MWT;   BBS;   TUG;   CGS and FGS;   SPDDS
8 Recruiting Long-Term Follow-Up Study for Safety, Efficacy and Tolerability of Rotigotine in Adolescents With Restless Legs Syndrome
Condition: Restless Legs Syndrome
Intervention: Drug: Rotigotine
Outcome Measures: Withdrawal Due to An Adverse Event (AE) From Visit 1 (Day 1) Through End of Study;   Occurrence of At Least One Adverse Event (AE) From Visit 1 (Day 1) to End of Study
9 Recruiting Pharmacokinetics and Safety Study of LY03003 in Patients With Early-stage Parkinson's Disease
Condition: Parkinson's Disease
Interventions: Drug: LY03003;   Drug: Neupro
Outcome Measures: Cmax for the Pharmacokinetics (PK) of LY03003;   Number of Participants with Adverse Events as a Measure of Safety and Tolerability;   Preliminary efficacy evaluation will be carried out based on Unified Parkinson's Disease Rating Scale (UPDRS) motor score (Part III)
10 Unknown  Measuring the Effects of Continuous Dopaminergic Stimulation on Nocturnal Movements in Parkinson's Disease
Conditions: Nocturnal Hypokinesia;   Parkinsons's Disease;   Rotigotine
Intervention:
Outcome Measures: Position changes over the night.;   • Degree of mobility, measured as the speed of the movements;   • Total amount of movements;   • Score on the motor symptom scale according to the MDS-UPDRS part III
11 Not yet recruiting Butrans for Treatment of Restless Legs Syndrome
Condition: Restless Legs Syndrome
Interventions: Drug: buprenorphine transdermal delivery system (BTDS);   Drug: Placebo for BTDS patch
Outcome Measures: The International Restless Legs Scale (IRLS);   Clinical Global Impression of Improvement

These studies may lead to new treatments and are adding insight into Neupro etiology and treatment.

A major focus of Neupro research is the development of new drugs and other treatment options. Studies seek to identify new drugs to treat various related disorders and to find safer, more effective doses for medications already being used. Other research is aimed at identifying receptors or drug targets.


Discuss Neupro